Home › Compare › SAFLY vs ABBV
SAFLY yields 50.31% · ABBV yields 3.06%● Live data
📍 SAFLY pulled ahead of the other in Year 1
Combined, SAFLY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SAFLY + ABBV for your $10,000?
Safilo Group S.p.A. engages in the design, production, wholesale, and retail distribution of products for the eyewear market in North America, Europe, the Asia Pacific, and internationally. Its brand portfolio comprises a set of own branded products, such as optical frames, sunglasses, sports goggles, and helmets, as well as licensed brands,including prescription frames and sunglasses. The company offers its products under own brands comprising Carrera, Polaroid, Safilo, Smith, Blenders Eyewear, and Privé Revaux, as well as Adensco, Chesterfield, Elasta, and Emozioni; and licensed brands, such as Banana Republic, BOSS, Carolina Herrera, Chiara Ferragni, David Beckham, Dsquared2, Fossil, havaianas, HUGO, Isabel Marant, Jimmy Choo, Juicy Couture, Kate Spade, LEVI'S, Liz Claiborne, Marc Jacobs, Missoni, M Missoni, Moschino and Love Moschino, Pierre Cardin, PORTS, rag&bone, Rebecca Minkof, Tommy Hilfiger, Tommy Jeans, Under Armour, and Liz Claiborne brand. It serves opticians, optometrists, ophthalmologists, distribution chains, department stores, specialized retailers, and licensors' own stores, as well as duty free and sports shops. The company sells its products through a network of independent distributor partners. The company was formerly known as Safilo Holding S.p.A. and changed its name to Safilo Group S.p.A. in September 2005. Safilo Group S.p.A. was founded in 1878 and is headquartered in Padua, Italy.
Full SAFLY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.